Top Markets
Coin of the day
Biostax Corp. Biostax Corp.

Biostax Corp.

BTAX
Classement en actions #41904
Biostax Corp. is a biopharmaceutical enterprise dedicated to the acquisition,... Biostax Corp. is a biopharmaceutical enterprise dedicated to the acquisition, advancement, and commercialization of various pharmaceutical and biotechnology solutions. A pivotal focus lies on Lodonal, their lead investigational drug candidate, designed as a once-daily immune system modulator aimed at managing both human immunodeficiency virus and acquired immune deficiency syndrome (HIV/AIDS). Beyond this primary drug, their portfolio encompasses several innovative programs. These include a Global Telehealth platform and an early-stage Medtech initiative leveraging blockchain and smart contract technologies to enhance the security and management of prescriptions and electronic health records. Furthermore, Biostax is developing JKB-122, an experimental small molecule that acts as a long-duration toll-like receptor 4 (TLR4) antagonist, intended for the treatment of autoimmune hepatitis, nonalcoholic fatty liver disease (NAFLD), and nonalcoholic steatohepatitis (NASH). Another compound they address is Low Dose Naltrexone, a formula believed to offer immune-modulating advantages pertinent to conditions such as cancer, chronic pain, autoimmune disorders, and anti-aging efforts. The company also pursues development efforts for addressing hyperphosphatemia. Biostax maintains a licensing agreement with Cytocom Inc. and underwent a corporate name change from Immune Therapeutics, Inc. to its current designation in October 2023. The company's operational base is located in Winter Park, Florida.
Prix de l'action
$0.0001
Dernière synchronisation: 2026-08-11
Capitalisation boursière
$7.87K
Changement (1 jour)
0.00%
Changement (1 an)
-50.00%
Pays
US
Échange Biostax Corp. (BTAX)

Catégorie

Ratio P/S pour Biostax Corp. (BTAX)
Ratio P/S au 2026 TTM : 0
Selon les derniers rapports financiers et le cours de l'action de Biostax Corp., le ratio cours/ventes actuel (TTM) est 0. À la fin de 2026, le ratio P/S était de 0.
Historique du ratio P/S pour Biostax Corp. de 2026 à 2026
Ratio P/S à la fin de chaque année
Année Ratio P/S Changez
Pas assez de données pour les dates fournies.
Ratio P/S pour des entreprises similaires ou concurrentes
Entreprise Ratio P/S Différence de Ratio P/S Pays
9.88 -
US
10.30 -
NL
- -
CH
4.98 -
BE
- -
KR